Current Edition

Biocon

Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses

Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …

Continue Reading →
antibody drugs

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …

Continue Reading →
Biocon

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …

Continue Reading →